The S$21M Buyback: Four Generations of Eu Yan Sang

Richard was 43 years old. He had joined Eu Yan Sang as general manager only the year before, leaving a career that had moved through merchant banking, stockbroking, and venture capital. His father had warned him against the family business: “Forget it — the politics are too bad.” Richard had ignored him. Within months, the politics his father warned about had delivered the company to property developers.

His uncles had done this. Third-generation men who had dismissed traditional Chinese medicine as a sunset industry and sold their shares to the highest bidder. The hostile takeover blindsided the family. But it also created the conditions for what happened next: a S$21 million leveraged buyback, a three-decade transformation, and a S$808 million exit that returned 38 times the rescue price.

The inheritance trap

I held a totally contrarian view. I believed the problem wasn't TCM itself but how it was presented.

The seeds of the 1990 crisis were planted half a century earlier. When patriarch Eu Tong Sen died in Hong Kong on May 11, 1941, he left behind an empire that was among the largest in Southeast Asia. Tin mining operations employing 12,000 workers. Lee Wah Bank. Real estate holdings across Malaya and Hong Kong. Entertainment venues. And the Chinese medicine business his father Eu Kong had founded in 1879 in Gopeng, a tin-mining town in Perak — a small shop selling herbal remedies to cure the opium addiction that ravaged Chinese miners under colonial-era conditions.

Eu Tong Sen also left behind 11 wives and 13 sons.

The arithmetic of fragmentation was brutal. By 1973, most family assets had been liquidated — Lee Wah Bank merged with United Overseas Bank, the real estate portfolio was sold, the tin mines that had once employed 12,000 workers were closed. Only Eu Yan Sang remained in family hands, and barely. The medicine halls had stagnated for sixty years: dim interiors, wooden drawers of dried herbs, elderly shopkeepers who spoke only Cantonese dialects. No new stores had opened since the pre-war era. The brand’s founding mission — 余仁生, “Caring for Mankind” — had become an artifact rather than an operating principle.

This is the pattern that destroys multi-generational family businesses. Not market failure. Not competition. Inheritance fragmentation — too many heirs, too little shared purpose, and a business that the majority views as a burden rather than an opportunity. The uncles who sold to Lum Chang weren’t betraying the family. They were liquidating what they considered worthless.

The contrarian buyback

Richard Eu held what he called “a totally contrarian view.” He believed the problem wasn’t TCM itself — it was how TCM was presented. The dusty halls, the mysterious herbs, the practitioners who couldn’t explain their treatments in modern terms — all of this could change. Ancient formulas that had worked for centuries could be validated by modern science. Retail experiences that repelled younger consumers could be reimagined. “I held a totally contrarian view,” he later told Mothership.SG. “I believed the problem wasn’t TCM itself but how it was presented.”

When Richard discovered that Lum Chang wanted only the listed shell and properties, not the TCM operations, the rescue path emerged. Lum Chang promised to sell the medicine business back to the Eu family when ready. In 1993, Richard allied with cousins Robert and Clifford Eu to execute a S$21 million leveraged buyout using their own capital. They deliberately excluded the older generation whose politics had created the crisis. The fourth generation now controlled Eu Yan Sang. They had inherited not a thriving business but a mandate to reinvent one.

The renovation was systematic. Richard’s diverse pre-Eu Yan Sang career proved formative — merchant banking taught financial structuring, stockbroking taught market positioning, and venture capital taught how to evaluate businesses with unproven models. He studied luxury retail — the clean lines of Chanel, the welcoming brightness of LVMH flagships — and applied those principles to medicine halls. Out went the dim interiors. In came bright lighting, clean displays, trained staff who could explain products in English as well as Chinese. Six inconsistent logos became one unified brand identity with the crane symbol. Loose herbs requiring hours of preparation became teabags for office workers. Traditional formulas were encapsulated for modern dosing. Ready-to-drink bird’s nest in elegant bottles replaced laborious home preparation.

The strategic centerpiece was scientific validation. Eu Yan Sang established clinical research partnerships with the Chinese University of Hong Kong, Hong Kong Baptist University, the National University of Singapore, and China Medical University. The century-old Bak Foong Pills — a women’s health formula combining 20-plus herbs including ginseng and angelica — underwent randomized controlled trials, generating peer-reviewed publications that gave the product clinical credibility no marketing campaign could replicate. Bo Ying Compound, an infant soothing remedy, was approved for the China market in 1998. Australia’s TGA standard — among the world’s strictest pharmaceutical regulations — was adopted years before competitors saw the value. Herb fingerprinting technology verified ingredient authenticity in ways traditional sourcing never could.

Building a company no one could strip for parts

The 2000 listing on the Singapore Exchange provided capital for the next phase. TCM clinics launched in 2001 — modern healthcare facilities where licensed practitioners combined traditional pulse-reading with Western diagnostic tools including X-ray interpretation and electro-acupoint diagnostics. The integrative medicine model was not merely positioning. It was a genuine attempt to bridge the epistemological gap between Eastern and Western medical traditions in a clinical setting.

A HK$110 million factory opened in Yuen Long, Hong Kong, in 2006 — a 130,000-square-foot GMP-certified, pharmaceutical-grade facility. A second factory operated through Weng Li Sdn Bhd in Malaysia, established in 1980. EYSGAP-Herbs, a proprietary sourcing certification, imposed standards that unqualified suppliers couldn’t meet and created the supply-chain quality assurance that institutional buyers would later require.

By 2006, Forbes Asia named Eu Yan Sang among its “Best Under a Billion” companies. Richard Eu won the Ernst & Young Entrepreneur of the Year award in Singapore in 2011, and CEO of the Year at the Singapore Corporate Awards in 2010. Revenue reached S$297 million by 2023 with S$18.7 million net profit. The workforce grew to 1,357 employees, including more than 50 licensed TCM practitioners. The product range expanded to 900 SKUs spanning traditional medicines, dietary supplements, health foods, wellness teas, and the ZING spa personal care brand.

The vertical integration served a purpose beyond operational efficiency. It made the company acquirable by someone other than a property developer. In 1990, Eu Yan Sang’s value was its real estate and its listed shell — a company worth more dead than alive. By 2024, its value was a supply chain that stretched from EYSGAP-certified herb farms to 170+ retail outlets to 30 clinics to four GMP-certified factories across Singapore, Malaysia, Hong Kong, and Macau. No single component could be stripped out and sold — the value was in the integration. The clinics generated recurring patient relationships that fed product sales. The factories ensured quality control that supported clinical research. The research generated peer-reviewed evidence that justified premium pricing. And the premium pricing funded the next round of research, clinical expansion, and factory investment. The flywheel was self-reinforcing — and that was precisely what made Eu Yan Sang attractive to a buyer with the resources to accelerate it.

The competitive landscape reinforced the positioning. Eu Yan Sang’s primary competitor, Beijing Tong Ren Tang, held 350+ years of heritage and 1,000+ stores — but its Southeast Asian presence was minimal, with only three stores in Malaysia through a Hai-O joint venture. In Hong Kong, Eu Yan Sang competed roughly equally with Wai Yuen Tong and Vita Green. But no competitor matched the combination of heritage, scientific validation, and vertical integration that the fourth generation had assembled.

The privatization bridge

In 2016, Richard Eu made a decision that proved critical to the eventual exit. He took the company private through a partnership with Tower Capital Asia and Temasek — Singapore’s sovereign wealth fund. The privatization provided the capital and operational freedom to accelerate the transformation without quarterly earnings pressure from public markets.

The 2016–2024 period was the interval that converted a well-run regional TCM company into an institutional-grade acquisition target. Free from SGX reporting requirements, management invested in digital transformation, expanded the clinic network, and strengthened the scientific validation programme. The privatization price became the baseline against which the 2024 exit would be measured — and the result tripled the 2016 valuation.

Richard later articulated the philosophy behind his willingness to dilute family control: “We are not a family business, we are a business family. Because the business might change but the family stays.” The distinction is not semantic. A family business protects family control. A business family protects the enterprise — and accepts that different ownership structures serve the enterprise at different stages. Richard’s willingness to move from family control (1993) to public markets (2000) to private equity partnership (2016) to strategic sale (2024) followed this philosophy at each transition.

The Japanese bet on Chinese medicine

In June 2024, a consortium led by Rohto Pharmaceutical (~60%) and Mitsui & Co. (~30%) acquired 86% of Eu Yan Sang for S$808 million. The Eu family retained approximately 10%. Richard Eu, then 77, continued as Chairman.

The buyer profile matters. This was not a financial investor seeking returns. Rohto is a Japanese pharmaceutical company with R&D capabilities that can accelerate Eu Yan Sang’s scientific validation program — taking the clinical research partnerships with CUHK and NUS to pharmaceutical-grade rigour. Mitsui is a trading house with distribution networks across Asia. The combination offers what the fourth generation built toward but couldn’t achieve alone: pharmaceutical-grade research and continental-scale distribution for a heritage TCM brand.

The retention structure tells its own story. Richard staying as Chairman, the family keeping 10% — these are not decorative gestures. They reflect a buyer that understood the brand’s value is inseparable from its heritage narrative. A Japanese consortium acquiring a 145-year-old Chinese medicine company is culturally sensitive — TCM is not recognised under Japan’s Kampo framework, and the regulatory path to Japanese market integration requires careful navigation. The family’s continued presence provides continuity that no amount of due diligence can substitute for. In 2020, Richard had received Singapore’s Public Service Medal — institutional recognition that confirmed the brand’s social contribution extended beyond commerce.

What 145 years taught the Eu family

Eu Yan Sang has now survived four distinct succession crises. The founder Eu Kong’s early death at 37 in 1890, leaving a fledgling medicine business to his son. The patriarch Eu Tong Sen’s estate fragmented among 13 heirs from 11 wives. A hostile takeover by property developers who valued the real estate more than the heritage. And the strategic privatization and eventual sale to institutional buyers that concluded the fourth generation’s stewardship.

Each crisis was different. Each required a different response. But three patterns held constant.

Heritage is not a constraint — it’s the moat. Every generation that tried to escape the TCM identity (the third-generation uncles who sold out) destroyed value. Every generation that modernized the heritage (Richard’s retail redesign, scientific validation, clinical integration) created it. The S$808 million exit was not a premium paid for stores or factories. It was a premium paid for 145 years of brand trust — 余仁生, “Caring for Mankind” — that no competitor can replicate.

Family control must yield to institutional discipline. The 2000 SGX listing, the 2016 privatization with Temasek, the 2024 Rohto-Mitsui acquisition — each step moved further from family control and closer to institutional governance. Richard’s willingness to accept this progression, rather than cling to majority ownership, made each successive transition possible. The philosophy that guided each step — “the business might change but the family stays” — proved both commercially and emotionally correct.

The buyback was the succession. The S$21 million leveraged buyout in 1993 was not just a rescue operation. It was the moment the fourth generation chose to be successors rather than inheritors. The distinction matters. Inheritors receive a business. Successors take responsibility for one. Richard, Robert, and Clifford chose responsibility — and the S$808 million exit, 31 years later, was the return on that choice.

For investors evaluating heritage brands in emerging markets, the Eu Yan Sang story offers a structural lesson: the value in heritage is not the heritage itself. It is the modernization infrastructure built around it. A 145-year-old brand name without scientific validation, vertical integration, and institutional governance is a relic. A 145-year-old brand name with all three is an acquisition-grade platform. The difference between the two is not time. It is the quality of stewardship — and the willingness of each generation to adapt the form of ownership while preserving the founding mission.

For the full story of how a Hakka immigrant’s opium cure became Southeast Asia’s largest TCM enterprise, read the Eu Yan Sang brand profile on brandmine.ai.

Last updated: June 4, 2026